Amy Chang

Amy Chang is an Executive Director in Oncology Drug Development at Eli Lilly and Company. They have extensive experience in oncology, having served as a Medical Monitor for novel therapeutic clinical trials and as a Hematology and Oncology Fellow at the University of Michigan with a focus on gastrointestinal malignancies. Previously, Chang was a Research Scientist at the University of Washington, where they contributed to projects on tumor vaccine development and immunomodulatory effects. Their academic background includes an M.D. from the University of Washington - School of Medicine, where they graduated in 2015.